Implications of the New Cholesterol Guidelines and CV Outcomes Trials to Improve Management of Patients at Risk of ASCVD Events

Presentations will provide detailed information on recent CVD outcomes trials, especially those that have proven benefits and provide new options.
Presentations will provide detailed information on recent CVD outcomes trials, especially those that have proven benefits and provide new options.
Enroll in this meeting
October 29, 2019
06:00 PM - 08:30 PM EDT
Gaylord National Resort & Convention Center
Room: National Harbor 12-13, 201 Waterfront Street, National Harbor, Maryland, United States
Enrollment Fee: Free
Free
  • Overview

    This 1.5-hour symposium will feature nationally recognized leaders in the management of atherosclerotic cardiovascular disease (ASCVD) risk, sharing the latest evidence and clinical practice pearls with managed care pharmacists.

    The program will include an introduction to the new 2018 Blood Cholesterol guides, examining what is new, and discussing the management algorithm for primary and secondary prevention.

    Presentations will also provide detailed information on recent CVD outcomes trials, especially those that have proven benefits and provide new options for ASCVD management.

    A perspective for the managed care pharmacist, incorporating the guidelines, recent data, and managed care implications, will give attendees an educated framework for their decision making in this area.

    Relevant clinical practice issues and challenges will also be addressed.

  • Learning Objectives

    At the conclusion of this activity, learners should be better able to:

    • Have greater clarity on implementing the new 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
    • Describe the spectrum of major recent ASCVD randomized cardiovascular outcomes trials
    • Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
    • Apply evidence-based guidelines, recent randomized clinical trial evidence, and cost implications to therapeutic approaches for managing patients at high risk of cardiovascular events
  • Agenda

    6:00 PM Registration and Buffet Dinner

    6:30 PM Program Overview

    6:40 PM New Cholesterol Guidelines: What You Should Know

    7:00 PM Roundup of Recent Clinical Trial Evidence to Reduce ASCVD Events

    7:20 PM Omega-3 FAs and Their Use in Patients with ASCVD

    7:40 PM Panel Discussion and Q&A

    8:10 PM Personalization of Care in ASCVD

    8:30 PM Program Adjourns

  • Target Audience

    This activity is intended for managed care pharmacists, health plan administrators, medical directors, physicians, nurses, administrators with accountable care organizations (ACOs), integrated delivery networks (IDNs), value-based national account managers, formulary decision makers, Medicare Part D and Medicaid administrators.

  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement 

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medtelligence. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), and the Accreditation Council for Pharmacy Education (ACPE).

    Physician Continuing Medical Education
    The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Continuing Pharmacy Education
    Postgraduate Institute for Medicine designates this continuing education activity for ___ contact hour(s) (0.___ CEUs) of the Accreditation Council for Pharmacy Education.
    (Universal Activity Number - xxxxxxx-xxx-xx-xxx-xxx)
    Type of Activity: Knowledge


    Interprofessional Continuing Education
    This activity was planned by and for the healthcare team, and learners will receive ___ Interprofessional Continuing Education (IPCE) credit for learning and change.

     



    .

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

  • American Disabilities Act

    Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Jessica McGrory prior to the live event at jmcgrory@omnia-prova.com.

Facebook Comments

Sign up for the Medtelligence newsletters.
Comprehensive Cardiology Education.

Better education for a better you.

* Required
Optional
Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free